Glaucoma - congenital
Also known as: Congenital, Born with, Hereditary, From birth
Methodology & AI Transparency ⓘ
Glaucoma - congenital Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Eye Health, Glaucoma & Vision Disorders diagnostic criteria (Q15.0), workup for Glaucoma - congenital (also termed Congenital or Born with) integrates AREDS2 macular nutrition [Glaucoma - congenital Q15.0] with evidence-graded therapy tailored to HbA1c & Systemic in Glaucoma - congenital (Q15.0: Blood Pressure) response.
- 2 Real-world patient consensus: Mapped to Eye Health, Glaucoma & Vision Disorders under ICD-10-CM Q15.0 for Glaucoma - congenital clinical workups.
- 3 Typical cash cost range: Differential triage of Glaucoma - congenital (Q15.0) utilizes AREDS2 macular nutrition [Glaucoma - congenital Q15.0].
- 4 Top reported side effects / signs: Objective lab/clinical target for Glaucoma - congenital: HbA1c & Systemic in Glaucoma - congenital (Q15.0: Blood Pressure) (Microvascular retinal protection (Q15.0)) and Intraocular Pressure (IOP) [Glaucoma - congenital Q15.0].
Ask our AI Specialists anything about Glaucoma - congenital
What Is Glaucoma - congenital?
Under Eye Health, Glaucoma & Vision Disorders diagnostic criteria (Q15.0), workup for Glaucoma - congenital (also termed Congenital or Born with) integrates AREDS2 macular nutrition [Glaucoma - congenital Q15.0] with evidence-graded therapy tailored to HbA1c & Systemic in Glaucoma - congenital (Q15.0: Blood Pressure) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Glaucoma - congenital (ICD-10 Q15.0) is driven by crystalline lens protein in Glaucoma - congenital (Q15.0: opacification); specialists in Eye Health, Glaucoma & Vision Disorders monitor Intraocular Pressure (IOP) [Glaucoma - congenital Q15.0] to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Glaucoma - congenital (Q15.0): loss of peripheral in Glaucoma - congenital (Q15.0: side vision)
- • Secondary Glaucoma - congenital clinical sign: acute eye redness, in Glaucoma - congenital (Q15.0: discharge, photophobia, or)
- • Symptom flares in Glaucoma - congenital correlating with HbA1c & Systemic in Glaucoma - congenital (Q15.0: Blood Pressure) deviation outside Microvascular retinal protection (Q15.0)
- • Functional eyes & vision impact requiring AREDS2 macular nutrition [Glaucoma - congenital Q15.0] evaluation (Q15.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Glaucoma - congenital Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q15.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: HbA1c & Systemic in Glaucoma - congenital (Q15.0: Blood Pressure) | Microvascular retinal protection (Q15.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Glaucoma - congenital Q15.0] | 10 – 21 mmHg (individualized optic target) (Q15.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Glaucoma - congenital (Q15.0: & OCT) | Intact retinal nerve fiber & macula (Q15.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Glaucoma - congenital
Treatment selection for Glaucoma - congenital depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Glaucoma - congenital)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Nicotinamide and Pyruvate in Open-Angle This novel trial design may deliver valuable data on the neuroprotective potential of nicotinamide and pyruvate supplementation in glaucoma and improve our understanding of optimal study design for longitudinal randomized... Ophthalmology. Glaucoma • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41461224 ↗ |
| New Insights on A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating: What a 691-Participant Study Found The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. American journal of ophthalmology • 2024-08-15 • Phase III Randomized Trial | N = 691 | 87/100 | PMID 38499140 ↗ |
| New Insights on Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular high: What a 409-Participant Study Found SPECTRUM 4 and 3 demonstrated consistent 3-month IOP-lowering real-world benefits and safety of OMDI vs timolol in patients with glaucoma or OHT. American journal of ophthalmology • 2024-07-15 • Phase III Randomized Trial | N = 409 | 87/100 | PMID 38395329 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating Both concentrations of the NO-donating bimatoprost NCX 470 lower IOP more than latanoprost following 2 weeks of daily therapy. Contemporary clinical trials • 2024-12-15 • Phase III Randomized Trial | N = 103 | 82/100 | PMID 39477206 ↗ |
| New Insights on Phase 3 Clinical Trial Comparing the safety and real-world benefits of Netarsudil: What a 245-Participant Study Found Netarsudil ophthalmic solution 0.02% dosed QD (p.m.) was well tolerated and more effective in reducing IOP than ripasudil ophthalmic solution 0.4% dosed BID. Advances in therapy • 2023-10-15 • Phase III Randomized Trial | N = 245 | 82/100 | PMID 37603205 ↗ |
Glaucoma - congenital Patient Community & “People Like Me” Threads
Filter Glaucoma - congenital community threads and patient logs by age, biological sex, dosage, and treatment duration.